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Anti-inflammatory and combined anti-
inflammatory/analgesic medication in the early
management of iliotibial band friction syndrome
A clinical trial
M. P. SCHWELLNUS, L. THEUNISSEN, 1. D. NOAKES, s. G. REINACH
Summary
Forty-three athletes presenting with unilateral iliotibial band
friction syndrome (ITBFS) were randomly divided into three
groups for the first 7 days of treatment (placebo-controlled,
double-blind): 1 - placebo (N = 13); 2 - anti-inflammatory
medication (N = 14) (Voharen; Geigy); and 3 - analgesicl
anti-inflammatory combined medication (N =. 16) (Myprodol;
Rio Ethicals). All subjects rested from day 0 to day 7 and all
groups received the same physiotherapy outpatient treatment
programme from day 3 to day 7. On days 0, 3 and 7 the
subjects performed a functional treadmill running test (maxi-
mum 30 minutes) during which they reported pain (scale
0-10; 0 = no pain, 10 = unbearable pain) each minute. Total
running distance, total running time and the area under the
pain v. time curve was calculated. Daily 24-hour recall pain
scores were also recorded. The 24-hour recall pain scores
deCreased significantly for all the groups over the treatment
period. This method of assessing efficacy of treatment there-
fore failed to show differences between groups. In contrast,
during the running test only group 3 improved their total
running time and distance from day 0 to day 7, whereas in all
the groups the area under the pain v. time curve decreased
from day 0 to day 7. All the other groups improved total
running time and running distance from day 3 to day 7. All
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three treatment modalities are effective in the early. treatment
of ITBFS but physiotherapy in combination with analgesicl
anti-inflammatory medication is superior. A functional running
test, which is more sensitive than conventional pain-recall·
methods in assessing efficacy of treatment in this type of
clinical trial, is described.
S Afr Med J 1991; 79: 602-606.
Iliotibial band friction syndrome (ITBFS) is a well-described
overuse injury of the knee. l - s It is commonly seen in distance
runners (4 - 7% of lower extremi~ injuries):'s but has also
been described in military recruits, ,9 weight lifters,4 downhill
skiers4 and athletes engaged in circuit training. 4 The anatomy
of the iliotibial tract,IO and the clinical presentation of ITBFS
have been well described. l - s.lI .
The postulated mechanism of injury in ITBFS is repetitive
friction of the iliotibial band as it moves over the prominent
lateral femoral epicondyle during flexion/extension movements
of the knee.4,6 This frictional movement may be exacer!Jated
by factors such as training errors,6 genu varus,7 cavus foot, II
leg length discrepancy,7 road camber7 and hard running shoes.7
The pathology of ITBFS is inflammation under, the iliotibial
tract over the lateral epicondyle. This has been confIrmed by
macro- and microscopic fmdings. 4,6
The management of ITBFS is based on correction of the
underlying factors that exacerbate the injury, decreasing acti-
vity, stretching the iliotibial band,S treatment of the inflamma-
tion and a gradual return to activity. In a small group of
patients surgery is indicated.2
The inflammatory process can be treated with rest, ice, oral
anti-inflammatory medication, physiotherapy or local steroid
injection.3,6,s,II:12 It is important to treat the inflammation to
reduce the risk of permanent damage with scarring.2
The use of non-steroidal anti inflammatory drugs (NSAIDs)
to decrease the inflammatory process in spons injuries has
been well described. 13,14 Despite their widespread use, vey few
well-conducted clinical trials on the use of these drugs in
spans injuries have been reported. The major limitations of
these S:2;viousl~ reponed, s,tu~es are poorly defmed ~~ula­
tions; seventy of the mJunes not well defmed/6,17, 9,_ not
conducted as double-blind studies; 11,24 and measures of thera-
peutic response being subjective. 15-11,19-24 Furthermore, most
studies have been conducted on acute injuries and only one
studyl1 has documented the use of NSAIDs in overuse injuries.
Although conservative treatment with NSAIDs appears to
alleviate the symptoms associated with ITBFS after a few
days/,l2 there are no well-controlled clinical trials to substan-
tiate this. Furthermore, no studies have been conducted to
evaluate the use of physiotherapeutic modalities alone or in
comb"ination with anti-inflammatory medication in the treat-
ment of ITBFS. The use of combined analgesic/anti-inflam-
matory medication has also not been compared to anti-inflam-
matory medication alone in the management of spons injuries.
The primary aim of this study was to compare the use of
physiotherapeutic modalities alone or in combination with
anti-inflammatory medication (Voltaren; Geigy) or analgesic/
anti-inflammatory medication (Myprodol; Rio Ethicals) in the
early treatment of ITBFS. A secondary aim was to establish a
functional and sensitive test that could be used to assess the
efficacy of treatment of spons injuries to the lower limb.
Patients and methods
Patients presenting with unilateral ITBFS were recruited from
two spons injury clinics over a period of 9 months (April
1989 - December 1989). The two clinics were the Spons
Injury Clinic at the University of Cape Town Spons Centre
and the Biokinetic Centre at 1 Military Hospital, Voortrekker-
hoogte.
Only patients over the age of 18 years with a confirmed
clinical diagnosis of unilateral ITBFS were included in the
study. Pregnant patients, those with a history of hypersensi-
tivity to anti-inflammatory or analgesic medication, those with
peptic ulcer disease, asthma, haematological disease, hepatic or
renal disease, previous knee surgery, and those on concomitant
medical therapy were not included in the study.
Each patient was examined and the diagnosis of unilateral
ITBFS was made using the following diagnostic criteria:
(I) history of pain on the lateral aspect of the knee durin~
running;1,6,8 (il) tenderness over the lateral femoral condyle/·4.
(iil) tenderness over the lateral femoral condyle aggravated at
30° of the knee flexion;2 and (iv) normal examination of the
knee joint.
The severity of the condition was assessed by grading tl>.~
pain experienced during running as follows:1 grade 1 - pain
after the run but not restricting the distance or the speed of
running; grade 2 - pain during the run but not restricting the
distance or the speed of running; grade 3 - pain during the
run and severe enough to restrict distance or speed; and grade
4 - pain severe enough to prevent running. Only patients
complaining of grade 3 or 4 pain were included in the study.
Written informed consent was obtained from all the patients
acc3rding the guidelines suggested by the American College of
Spons Medicine.25 The study was approved by the Ethics and
Research Committee of the Faculty of Medicine of the Uni-
versity of Cape Town. A running history, which included the
following details, was obtained from all the patients: years of
running; duration of symptoms; weekly training distance; and
average training speed.
Fony-nine patients were entered into the trial and randomly
divided into three treatment groups (groups 1,2 and 3) for the
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flrst 7 days of treatment. Three subjects each from groups 1
and 2 were excluded from the fmal results. The reasons for
exclusion were: incomplete follow-up (4); severe side-effects
(1); and refusal to comply with the physiotherapy treatment
programme (1). The fmal number of subjects was fony-three.
All the'groups received treatment as outpatients. The treat-
ment consisted of rest, ice (twice daily local application) and
medication from day 0 to day 7. From Oay 3 to day 7 they also
received physiotherapy. The physiotherapy at the two centres
was the same. There were thus two distinct phases in the
treatment programme: day 0 to day 3 (rest, ice and medication
alone) and day 3 to day 7 (added physiotherapy). The physio-
therapyprogramme consisted of daily stretching of the iliotibial
band,5,2 daily ultrasonographyl2 to the tender area, and trans-
verse frictions to the area on days 3, 5 and 7. The value of
transverse frictions in this injury is not documented but was
included on the basis of anecdotal evidence that it might be
effective.
Medication was given for the 7-day period in a double-
blind, placebo-eontrolled fashion as follows: group 2 received
50 mg diclophenac sodium 3 times a day with meals. The
tablets were packed into capsules indistinguishable from the
capsules used by the other groups; group 3 received a similar
capsule containing 400 mg ibuprofen, 500 mg paracetamol and
20 mg codeine phosphate 3 times a day; and group 1 received
a placebo capsule 3 times a day. Compliance was monitored by
counting the capsules remaining in the containers on day 7.
The code with the identity of the capsules handed to each
patient was revealed only after the analysis of all the data was
completed.
The efflcacy of the treatment was assessed by two methods:
(I) conventional daily pain recall on a scale/1-29 and '(it) a
functional treadmill running test.
On the flrst visit the patient was familiarised with the pain
scale used for the daily pain recall and the treadmill running
test. The pain scale was a visual analogue scale from 0 to 10
where 0 represented no pain and 10 unbearable pain.21 Patients
were instructed to record their pain experienced at rest, during
walking and overall pain every day on a pain repon form. The
decrease in reponed pain was compared in the three groups.
The treadnill running test was performea on day 0, day 3
and day 7. The subjects were dressed in running shorts and
vests and wore the same running shoes for all tests. The
running speed was the same for each test on the 3 days for
each subject and was selected for each subject on the basis of
their average daily training speed. A walking test was used for
those subjects who" were unable to run. The gradient of the
treadmill was 0° for all the tests. The tests were always
performed at the same time of day (morning) and on the test
day the subjects were requested not to take their morning dose
of the medication until after the test was completed.
The test was preceded by a warm-up of 1 minute brisk
walking. During the test subjects were asked to repon each
minute on the pain they experienced and it was discontinued if .
the pain was of such a severity that it would normally decrease
the running speed or distance of a runner (7 - 8 on the pain
scale) or after 30 minutes of running. The subjects were free to
stop at any time but all complied with the running test
protocol as outlined above. The speed and distance run was
also recorded every minute.
The pain grading was plotted against time (minutes) for
each subject on days 0, 3 and 7. The area under the pain v.
time curve was calculated from the graphs using the minimum
time the subject could run on any of the 3 days (usually day
0). This area is an indication of the total pain experienced
during that time. These data were then compared between the
three groups and within groups over the 7-day period.
The adverse effects of the medication were assessed on the
3rd and 7th day by a personal interview conducted by the
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principal investigator. The following information was obtained:
description of symptoms; duration and severity of symptoms
(mild, moderate or severe); the relationship of symptoms to
the medication; and the management.
Statistical analysis
Statistical analysis was performed by the Institute for Bio-
statistics of the South Mrican Medical Research Council using
the BMPD package on the ISM 4381 mainframe computer.
Between-group comparison for physical characteristics, running
history, area under the pain/time curve, total running time,
total distance run, and daily reported pain was obtained by
one-way analysis of variance, after testing that there was no
sex-by-group interaction. Significant change over time (from
days 0 - 3, days 0 - 7 and days 3 - 7) for the variables within
groups was estimated by Wilcoxon's signed-rank test. The
level of significance was established at P < 0,05, since this is
considered a probing experiment. The test level was not
adapted according to Bonferroni for the number of com-
parisons being made.30
There was a significant decrease in pain scores in all three
groups from day 0 to day 2, day 0 to day 6 and day 3· to day 6
(Fig. 1).
The results of pain recorded during the treadmill running
test are shown in Figs 2, 3 and 4. The value for pain (area
under the pain v. time curve) for the three groups (Fig. 2) was
not significandy different between the groups on any of the
days. However, there was a significant decrease in the values
from day 0 to day 3 for group 3 only. From day 3 to day 7
there was a decrease in the values for groups 1 and 3 but not
group 2 and from day 0 to day 6 there was a significant
decrease in all three groups.
The total distance run did not differ significandy on each of
the test days between the groups (Fig. 3). In all three groups
the total distance run did not change significandy from day 0
to day 3 but did increase significandy from day 3 to day 7.
However, only in.group 3 was running- distance significandy




Table I summarises the age, height, weight and rwming
history of the subjects. in each group. There were no significant
differences between groups for years of running, average
weekly training distance or training speed. In particular, the
grade and duration of the injury at the onset of the study was









No significant differences were observed between groups.
The mean daily pain scores recorded for overall pain over
the treatment period in each group is depicted in Fig. 1. Pain
scores at rest and during walking displayed a similar pattern
and are therefore not shown. The initial mean scores in all
three groups decreased in the first 2 days, then were associated












Total running time did not differ significandy between
groups on each of the test days (Fig. '4). Group I showed a
significant reduction in running time from day 0 to day 3. The
running time was improved significandy in all the groups from
day 3 to day 7 but only group 3 showed. a significant
improvement from day 0 to day 7.
30
AREA (UNITS X MIN)
60
40
Fig. 1. The mean overall daily pain recorded in each group.
Significant differences (P < 0,05) are indicated as follows: day
0-2 *; day 0 - 6 **; and day 3 - 6 +.
DAY 3
DAYS
Fig. 2. The pain experienced during running (area under the pain
v. time curve) for the three groups on day 0, 3 and 7. Significant
differences are indicated as follows: day 0 - 3 *; day 0 - 7 **; and
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_ GROUP 1 ~ l3ROUP 2 0 GROUP 3
Clinical studies to evaluate the effectiveness of different anti-
inflammatory medications in sports injuries are mostly vague,
conflictin~ and difficult to interpret because: (z) a wide variety
of different injuries are usually studied; (iz) the severity of
injuries often differ; and (iiz) they rely on very subjective
criteria to measure the outcome of treatment. 14 ITBFS is a
well-defined, specific injury in which the severity can be
graded accurately on the basis of the symptoms.7 Its pathology
is an inflammatory process4.6 resulting in pain as the main
symptom. This injury is therefore an ideal 'model' that can be
used to study the effectiveness of different anti-inflammatory
or analgesic medications or both.
The principal findings of this study were that ITBFS is best
treated in the 1st week by a physiotherapy programme together
with combined analgesic/anti-inflammatory medication. Treat-
ment with physiotherapy alone was more effective than when
combined with anti-inflammatory medication although both
did result in improvement of the condition. In addition, a
successful and sensitive functional test is described, which'
evaluates the effectiveness of treatment in a lower extremity
overuse sports injury.
In this study the usual method of daily pain record assess-
ment showed a significant decrease in pain over the treatment
period in all three treatment groups. The only exception was
the pain recorded at rest in group 3. Based on this traditional
method of assessing outcome the effectiveness of the three
treatment protocols were similar.
In contrast the novel functional treadmill running test des-
cribed here did demonstrate differences in the response to
treatment in the three groups. Only group 3 showed a significant
improvement in running time and distance run from day 0 to
day 7. The values for pain on different days decreased signifi-
cantly for all the groups over the 7 days, perhaps indicating
that it is less sensitive than running time or running distance
in assessing outcome.
The positive effect of adding physiotherapeutic modalities
(ultrasonography and transverse frictions) to the treatment
programme is suggested by this study. Total running time and
total distance run were improved in all three groups from day
3 to day 7. The values for pain from day 3 to day 7 were also
improved in groups 1 and 3 but not group 2. The beneficial
effect of rest alone from day 3 to day 7 was not studied and
can therefore not be excluded as an additional factor to explain
improvement from day 3 to day 7.
The only medication that had an early effect on the functional
test was the combined analgesic/anti-inflammatory agent where























Fig. 3. Total distance run on each of the test days for the three
groups. Significant differences are indicated as follows: day
o. 3 *; day 0 • 7 **; and day 3· 7+.
Fig. 4. Total running time on each of the test days for the three
groups. Significant differences are indicated as follows: day
o. 3 *; day 0 • 7 **; and day 3 • 7+.
The side-effects associated with medication are reported for
the three groups in Table n. The incidence (side-effects/week)
was 38%, 28% and 23% for groups 1,2 and 3, respectively. The
most common side-effects were headache and nausea. Only 1
subject withdrew from the study because of severe nausea
(group 3).
TABLE 11. ADVERSE EFFECTS REPORTED IN EACH GROUP
Group Incidence Severity Relationship Symptoms
1 38% (5/13) Mild Unrelated Nausea
Mild Probable Headache
Mild Unrelated Fatigue
Mild Probable Abdominal pain
Mild Unrelated Dizziness




3 23% (4/17) Mild Definite Headache
Moderate Probable Sore throat
Moderate Definite Nausea
Severe Definite Nausea·
• Significant enough to withdraw from the study.
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scores decreased in all the groups during this period but
significant differences were not observed between the groups.
The reason for the better performance of the combined
analgesic/anti-inflammatory medication is not clear. The most
likely explanation is that a greater analgesic effect is achieved,
which would blunt the pain experienced during running and
other daily activities. However, it must be noted that the
running test was performed without the morning dose of the
medication and would have been at least 10 hours after the last
dose. The dose of anti-inflammatory drug administered was 50
mg 3 times a day - the recommended dose. A low dose could
therefore not account for its relatively poor performance.
Although the mean number of years of running wa::; higher
in group I than in the other two groups (not statistically
higher), it is most unlikely that this could account for dif-
ferences in treatment outcome. There is no evidence to indicate
that years of running affects prognosis in ITBFS.
The incidence of adverse effects was similar in all three
groups indicating that they were probably not related to the
medication. It must be noted that I subject on combined
analgesic/anti-inflammatory medication withdrew because of
severe nausea. The other adverse effects were mild and did not
affect the treatment outcome.
In summary, this study demonstrates that physiotherapy
(ultrasonography and cross friction) together with combined
analgesic/anti-inflammatory medication is the most effective
early treatment for athletes presenting with ITBFS. In addition,
a functional treadffiill running test is described, which is more
sensitive than conventional pain recall methods in assessing
efficacy of treatment in this type of clinical trial.
The authors wish to thank Adcock-Ingram Laboratories Ltd for
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